Published in Cancer Weekly, July 26th, 2005
The R&D licensing agreement totals 8.3 million Ren Min Bi to be paid in several installments of which approximately 85% will be paid by XinYu within the next 12 months. The remaining balance will then be paid upon the drug...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.